Get started
Author

Fabio Guolo

Observed names: F. Guolo, Fabio GUOLO, GUOLO, FABIO, Guolo, Fabio
Observed institutions: University of Insubria, University of Parma, Karolinska University Hospital, Instituto de Salud Carlos III, Hospital General Universitario Gregorio Marañón, Italian Foundation of Myelodysplastic Syndromes, Hospital Universitario Puerta de Hierro Majadahonda, University Medical Center Hamburg-Eppendorf, Hospital Universitario de Burgos, Ospedale Policlinico San Martino, King's College Hospital, Aziende Socio Sanitarie Territoriale dei Sette Laghi, IRCCS Azienda Ospedaliera Metropolitana, University of Genoa
ORCID: 0000-0003-3166-6078
Observed ORCID: 0000-0003-3166-6078
OpenAlex ID: A5006684853
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
2021 · Livio Pagano, Jon Salmanton-García, et al. · Journal of Hematology & Oncology · 317
PDF
Harnessing NK Cells for Cancer Treatment
2019 · Paola Minetto, Fabio Guolo, et al. · Frontiers in Immunology · 95
PDF
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia
2021 · Giovanni Martinelli, Cristina Papayannidis, et al. · Blood Advances · 77
PDF
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
2017 · Giovanni Martinelli, Alfonso Piciocchi, et al. · Blood · 70
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells’ vulnerability to DNA-damaging agents
2017 · Antonia Cagnetta, Debora Soncini, et al. · Haematologica · 61
PDF
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program
2020 · Fabio Guolo, Luana Fianchi, et al. · Blood Cancer Journal · 56
Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
2020 · Silvia Pesce, Sara Trabanelli, et al. · Cancers · 53
PDF
Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide
2017 · Anna Maria Raiola, Antonio Risitano, et al. · Transplantation and Cellular Therapy · 49
Safety and efficacy of 90 Y ttrium‐ I britumomab‐ T iuxetan for untreated follicular lymphoma patients. An I talian cooperative study
2013 · Adalberto Ibatici, Gian Matteo Pica, et al. · British Journal of Haematology · 37
PDF
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
2024 · Jon Salmanton-García, Francesco Marchesi, et al. · EClinicalMedicine · 36
PDF
Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia
2013 · Carlo Marani, Marino Clavio, et al. · Leukemia Research · 35
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia
2017 · Fabio Guolo, Paola Minetto, et al. · Haematologica · 34
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen
2020 · Patrizia Chiusolo, Stefania Bregante, et al. · American Journal of Hematology · 29
PDF
Amino acid depletion triggered by ʟ-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death
2020 · Debora Soncini, Paola Minetto, et al. · Blood Advances · 27
PDF
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
2023 · Davide Lazzarotto, Ilaria Tanasi, et al. · Annals of Hematology · 26
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients
2016 · Fabio Guolo, Paola Minetto, et al. · American Journal of Hematology · 23
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study
2022 · Michelina Dargenio, Massimiliano Bonifacio, et al. · British Journal of Haematology · 21
PDF
Performance of serum (1,3)‐ß‐ d ‐glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies
2018 · Elisa Furfaro, Daniele Roberto Giacobbe, et al. · Mycoses · 21
A blastic plasmacytoid dendritic cell neoplasm‐like phenotype identifies a subgroup of npm1‐mutated acute myeloid leukemia patients with worse prognosis
2017 · Paola Minetto, Fabio Guolo, et al. · American Journal of Hematology · 20
PDF
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
2023 · Giuseppe Rossi, Jon Salmanton-García, et al. · International Journal of Infectious Diseases · 19
PDF
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden
2020 · Paola Minetto, Anna Candoni, et al. · Cancers · 19
PDF
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
2024 · Thomas Cluzeau, Fabio Guolo, et al. · Blood Advances · 18
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
2019 · Debora Soncini, Stefania Orecchioni, et al. · Haematologica · 16
PDF
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin ( FLAI ) provides the most useful prognostic information
2018 · Paola Minetto, Fabio Guolo, et al. · British Journal of Haematology · 16
PDF
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia
2014 · Enrico De Astis, Marino Clavio, et al. · Annals of Hematology · 16
Works count: 180
Citation count: 1,542
H-index: 19
I10-index: 36
Year
Topic
Type